High incidence of protein-truncating TP53 mutations in BRCA1 -related breast cancer

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3625-3633

  Holstege, Henne ^a   Joosse, Simon A ^a   Van Oostrom, Conny Th M ^b   Nederlof, Petra M ^a   De Vries, Annemieke ^b   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; PROTEIN P53;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; EXON; FRAMESHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; NONSENSE MUTATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPLETION; SPLICING DEFECT; WILD TYPE;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, BRCA1; GENES, P53; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65949105079     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3426     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E. et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58: 71-96.
2. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J. Hum Genet 1997; 60: 1013-20. (Pubitemid 27194085)
3. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCA- ness' in sporadic cancers. Nat. Rev. Cancer 2004; 4: 814-9. (Pubitemid 39331153)
4. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-23. (Pubitemid 39551659)
5. Lane DP, Cancer. p 53, guardian of the genome. Nature 1992; 358: 15-6.
6. Schuyer M, Berns EM. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol. Cell Endocrinol. 1999; 155: 143-52. (Pubitemid 29460973)
7. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A, Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Breal, Brca2, Brcal/Brca2, Brcal/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997; 11: 1226-41. (Pubitemid 27235356)
8. 8 Suzuki A, de la Pompa JL, Hakem R. et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997; 111: 1242-52. (Pubitemid 27235357)
9. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of Brcal (5-6) early embryonic lethality by p 53 or p 21 null mutation. Nat Genet 1997; 16: 298-302. (Pubitemid 27280216)
10. Evers B, Jonkers J. Mouse models of BRCA1 and BKCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 2006; 25: 5885-97. (Pubitemid 44453444)
11. Liu X, Holstege H, van der Gulden H. et al. Somatic loss of BRCA1 and p 53 in mice induces mammary tumors with features of human BRCA1-mutated basallike breast cancer. Proc. Natl. Acad. Sci. U S A 2007; 104; 12111-6. (Pubitemid 47185638)
12. Jonkers J, Meuwissen R, van Der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Mat Genet 2001; 29: 418-25. (Pubitemid 34326692)
13. Xu X, Qiao W, Linke SP. et al. Genetic interactions between tumor suppressors Brcal and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001; 28: 66-71. (Pubitemid 32626030)
14. Smith PD, Crossland S, Parker G. et al. Novel p 53 mutants selected in RRCA-assoeiated tumours which dissociate transformation suppression from other wildtype p 53 functions. Oncogene 1999; 18: 2451-9. (Pubitemid 29206158)
15. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat 2003; 121: 301-6. (Pubitemid 36292972)
16. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001; 61: 4092-7. (Pubitemid 32720976)
17. Crook T, Brooks LA, Crossland S. et al. p 53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998; 17: 1681-9. (Pubitemid 28482645)
18. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p 53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9. (Pubitemid 20089305)
19. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p 53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
20. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p 53 exerts a dominant negative effect by preventing wildtype p53 from binding to the promoter of its target genes. Oncogene 2004; 23: 2330-8. (Pubitemid 38496788)
21. Visscher DW, Sarkar EH, Shimoyama RK, Crissman JD, Correlation between p 53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol. Pathol 1996; 5: 187-93. (Pubitemid 26323979)
22. Jacquemier J, Moles JP, Penault-Llorca F. et al. p 53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J. Cancer 1994; 9: 846-52. (Pubitemid 24140662)
23. Yandell DW, Thor AD. p 53 analysis in diagnostic pathology. Biologic implications and possible clinical applications. Diagn Mol. Pathol 1993; 2: 1-3. (Pubitemid 23197491)
24. Hall PA, Lane DP. p 53 in tumour pathology: can we trust immunohistochemistry?-Revisited! J. Pathol 1994; 172: 1-4. (Pubitemid 24074994)
25. Gretarsdottir S, Tryggvadottir L, Jonasson JG. et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J. Cancer 1996; 74: 555-61. (Pubitemid 26279049)
26. Alsner J, Jensen V, Kyndi M. et al. A comparison between p 53 accumulation determined hy immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008; 47: 600-7.
27. Armes JE, Trute L, White D. et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 999; 59: 2011-7. (Pubitemid 29186179)
28. Phillips KA, Nichol K, Ozcelik H. et al. Frequency of p 53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. 1J Natl Cancer Inst 1999; 91: 469-73. (Pubitemid 29128285)
29. Foulkes WD, Chappuis PO, Wong K. et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000; 11: 307-13. (Pubitemid 30214668)
30. Joosse SA, van Beers EH, Tielen IH. et al. Prediction of BRCA1-association in hereditary non-BRCAl/2 breast carcinomas with array-CGH. Breast Cancer Res Treat Epub 2008 Aug. 14.
31. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p 53. New monoclonal antibodies and epitope mapping using recombinant p 53. J. Immunol Methods 1992; 151: 237-44.
32. Petitjean A, Mathe E, Kato S. et al Impact of mutant p 53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-9. (Pubitemid 46744292)
33. Maquat LE, Carmichael GG. Quality control of mRNA function. Cell 2001; 104: 173-6. (Pubitemid 32174833)
34. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 63-74. (Pubitemid 32447869)
35. Walker DR, Bond JP, Tarone RE. et al. Evolutionary conservation and somatic mutation hotspot maps of p 53: correlation with p53 protein structural and functional features. Oncogene 1999; 18: 211-8. (Pubitemid 29060595)
36. Sobol H, Stoppa-Lyonnet D, Bressac-De Paillerets B. et al. BRCAl-p53 relationship in hereditary breast cancer. Int J. Oncol 1997; 10: 349-53. (Pubitemid 27080929)
37. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006; 34: 1416-26.
38. Langerod A, Zhao H, Borgan O. et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007; 9: R30. (Pubitemid 350215177)
39. Jong YJ, Li LH, Tsou MH. et al. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. Cancer Genet Cytogenet 2004; 148: 55-65. (Pubitemid 38018881)
40. Sigurdsson S, Bodvarsdottir SK, Anamthawat-Jonsson K. et al. p 53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genet Cytogenet 2000; 121: 150-5.
41. Eyfjord JE, Thorlacius S, Steinarsdottir M, Yalgardsdottir R, Ogmundsdottir HM, Anamthawat-Jonsson K, p 53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 1995; 55: 646-51.
42. Foulkes WD, Stefansson IM, Chappuis PO. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst 2003; 95: 1482-5. (Pubitemid 37279334)
43. Lakhani SR, Jacquemier J, Sloane JP. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst 1998; 90: 1138-45. (Pubitemid 28380718)
44. Olivier M, Langerod A, Carrieri P. et al. The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin. Cancer Res 2006; 12: 1157-67. (Pubitemid 43342504)
45. Poeta MI., Manola J, Goldwasser MA. et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J. Med 2007; 357: 2552-61. (Pubitemid 350294222)
46. Campeau PM, Foulkes WD, Tischkowite MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 2008; 124: 31-42.
47. Chen Z, Xiao Z, Gu WZ. et al. Selective Chkl inhibitors differentially sensitize p 53-deficient cancer cells to cancer therapeutics. Int J. Cancer 2006; 119: 2784-94.
48. Bertheau P, Turpin E, Rickman DS. et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubiehi-cyelophosphamide regimen. PLoS Med 2007; 4: e90. (Pubitemid 46495326)
49. Bertheau P, Plassa F, Espie M. et al. Effect of mutated TP53 on response of advanced breast cancers to highdose chemotherapy. Lancet 2002; 360: 852-4. (Pubitemid 35257951)
50. Kroger N, Milde-Langosch K, Riethdorf S. et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin. Cancer Res 2006; 12: 159-68. (Pubitemid 43166190)